Multisystem inflammatory syndrome
Methodology & AI Transparency ⓘ
Multisystem inflammatory syndrome Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as M35.81, Multisystem inflammatory syndrome falls under Autoimmune Disease management, where early treat-to-target disease-modifying in Multisystem inflammatory syndrome (M35.81: antirheumatic (DMARD/biologic) therapy) establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Multisystem inflammatory syndrome uses ICD-10 M35.81 across Autoimmune Disease specialty care.
- 3 Typical cash cost range: Differential triage of Multisystem inflammatory syndrome (M35.81) utilizes early treat-to-target disease-modifying in Multisystem inflammatory syndrome (M35.81: antirheumatic (DMARD/biologic) therapy).
- 4 Top reported side effects / signs: Objective lab/clinical target for Multisystem inflammatory syndrome: hs-CRP & ESR [Multisystem inflammatory syndrome M35.81] (hs-CRP < 1.0 mg/L; ESR < 15 mm/hr (M35.81)) and ANA, RF, Anti-CCP in Multisystem inflammatory syndrome (M35.81: & Complement C3/C4).
Ask our AI Specialists anything about Multisystem inflammatory syndrome
What Is Multisystem inflammatory syndrome?
Designated in federal medical registries as M35.81, Multisystem inflammatory syndrome falls under Autoimmune Disease management, where early treat-to-target disease-modifying in Multisystem inflammatory syndrome (M35.81: antirheumatic (DMARD/biologic) therapy) establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Multisystem inflammatory syndrome (ICD-10 M35.81) is driven by JAK-STAT) driving systemic in Multisystem inflammatory syndrome (M35.81: connective-tissue); specialists in Rheumatoid Arthritis, Lupus & Autoimmune monitor ANA, RF, Anti-CCP in Multisystem inflammatory syndrome (M35.81: & Complement C3/C4) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Multisystem inflammatory syndrome (M35.81): triphasic Raynaud color in Multisystem inflammatory syndrome (M35.81: changes in fingers)
- • Secondary Multisystem inflammatory syndrome clinical sign: prolonged morning joint in Multisystem inflammatory syndrome (M35.81: stiffness lasting over)
- • Symptom flares in Multisystem inflammatory syndrome correlating with hs-CRP & ESR [Multisystem inflammatory syndrome M35.81] deviation outside hs-CRP < 1.0 mg/L; ESR < 15 mm/hr (M35.81)
- • Functional autoimmune disease impact requiring early treat-to-target disease-modifying in Multisystem inflammatory syndrome (M35.81: antirheumatic (DMARD/biologic) therapy) evaluation (M35.81)
Multisystem inflammatory syndrome Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M35.81 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Rheumatoid Arthritis, Lupus & Autoimmune | NLM Clinical Tables |
| Diagnostic / Lab Marker: hs-CRP & ESR [Multisystem inflammatory syndrome M35.81] | hs-CRP < 1.0 mg/L; ESR < 15 mm/hr (M35.81) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ANA, RF, Anti-CCP in Multisystem inflammatory syndrome (M35.81: & Complement C3/C4) | Disease-activity remission targets (M35.81) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CBC, ALT & in Multisystem inflammatory syndrome (M35.81: Creatinine (DMARD safety)) | Within normal safety monitoring limits (M35.81) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Multisystem inflammatory syndrome
Treatment selection for Multisystem inflammatory syndrome depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Multisystem inflammatory syndrome)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Longitudinal modeling of efficacy response in patients with lupus nephritis For belimumab-treated patients, belimumab exposure was not found to be an important predictor of kidney response. Journal of pharmacokinetics and pharmacodynamics • 2024-06-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38551711 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Intravenous Golimumab in Ankylosing Spondylitis Patients Prompt diagnosis of AS and early treatment with IV golimumab may yield more robust improvements in disease activity. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases • 2022-08-01 • Phase III Randomized Trial | N = 60 | 88/100 | PMID 35653615 ↗ |
Multisystem inflammatory syndrome Patient Community & “People Like Me” Threads
Filter Multisystem inflammatory syndrome community threads and patient logs by age, biological sex, dosage, and treatment duration.